Senores Pharmaceuticals Peer Comparison

NSE: SENORES | BSE: 544319

₹1,175.00

₹-19.00 (-1.59%)

As on 09-Nov-2026IST

Market cap

₹5,402 Cr

Revenue (TTM)

₹722 Cr

P/E Ratio

40.5

P/B Ratio

5.4

Div. Yield

0 %

Edit

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Market cap (₹ Cr)	5,402	42,021	26,099	18,143	13,648
Revenue (₹ Cr)	722	10,234	2,307	2,684	710
Net Profit (₹ Cr)	137.30	1,092.67	452.55	669.74	188.64
Net Margin (%)	18.17	10.67	19.31	24.24	25.69
RoE (%)	13.79	21.65	23.18	19.79	20.46
Price to Earnings	40.47	38.43	57.67	27.09	72.47
Price-To-Book	5.39	7.86	12.86	5.00	14.26

Income Statement (₹ Cr)

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Operating Revenue	722.29	10,234.10	2,307.19	2,684.41	709.64
Total Income	755.49	10,245.27	2,343.69	2,763.43	734.34
Total Expenditure	509.38	8,141.47	1,602.28	1,761.70	458.93
EBITDA	212.91	2,092.63	704.92	922.70	250.72
Depreciation	37.35	430.12	104.34	82.27	17.12
EBIT	175.56	1,662.51	600.57	840.44	233.59
Interest	29.73	151.49	28.27	5.42	8.49
Other Income	33.20	11.17	36.50	79.02	24.69
Exceptional Items	0.00	-27.85	0.00	-25.66	0.00
Profit before Tax	179.03	1,494.35	608.80	888.39	249.79
Provision for Tax	41.73	401.68	156.25	218.65	61.16
Profit after Tax	137.30	1,092.67	452.55	669.74	188.64

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Shareholder's Funds	1,002.98	5,344.04	2,029.71	3,631.29	957.32
Minority Interest	-3.82	0.82	0.00	0.00	-0.30
Non-Current Liabilities	237.48	980.81	381.27	146.95	106.92
Current Liabilities	411.59	3,838.93	618.58	563.70	248.88
Total Liabilities	1,603.81	9,514.48	2,930.14	4,157.10	1,174.38

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Non-Current Assets	867.04	3,542.74	1,471.67	1,454.42	534.87
Current Assets	766.31	6,027.59	1,389.85	2,864.85	723.33
Total Assets	1,603.81	9,514.48	2,930.14	4,157.10	1,174.38
Total Debt*	327.09	1,204.08	196.61	0.00	148.29
Net Current Assets	354.72	2,188.66	771.28	2,301.15	474.44
Contingent Liabilities	24.43	258.92	13.18	4.82	--

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Cash From Operating Activities	62.05	943.55	346.68	565.41	69.55
Cash Flow from Investing Activities	-120.56	-1,193.06	-423.73	-570.15	-330.93
Cash from Financing Activities	-1.33	343.43	20.98	-64.34	247.29
Net Cash Inflow / Outflow	-59.84	93.92	-56.08	-69.08	-14.09

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
ROCE (%)	15.66	25.25	27.50	24.61	28.50
ROE (%)	13.79	21.65	23.18	19.79	20.46
ROA (%)	9.25	11.17	16.27	16.78	16.29
EBIT Margin (%)	24.31	16.24	26.03	31.31	32.92
Net Margin (%)	18.17	10.67	19.31	24.24	25.69
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Revenue Growth (%)	43.39	21.12	50.46	8.19	26.57
EBIT Growth (%)	90.76	32.84	138.53	24.77	26.37
Net Profit Growth (%)	60.23	33.33	88.45	26.27	24.97
EPS Growth (%)	53.23	38.63	131.13	29.79	8.48
Book Value Growth (%)	18.71	11.36	22.95	18.43	79.97

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Price / Earnings	40.47	37.70	57.67	26.21	72.47
Price / Book Value	5.39	7.86	12.86	4.98	14.26
Dividend Yield (%)	0.00	0.16	0.17	0.34	0.12
EV/EBITDA	26.16	20.59	36.80	18.76	54.57
Market Cap (₹ Cr)	3,490.16	30,257.56	15,412.11	11,956.86	6,690.53

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Debt to Equity	0.21	0.10	0.10	0.00	0.07
Short term debt to equity ratio	0.03	0.16	--	--	0.12
Current Ratio	1.86	1.57	2.25	5.08	2.91
Quick Ratio	1.62	0.92	1.35	3.69	1.80
Interest Coverage	7.02	10.86	22.53	165.03	30.42

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Debtors to sales (%)	35.06	26.69	12.76	36.81	34.68
Asset Turnover	0.49	1.05	0.83	0.67	0.61
Receivable days	129.44	88.68	77.32	144.58	115.16
Inventory Days	42.09	84.11	80.83	96.67	96.15
Payable days	218.97	176.65	125.94	135.45	106.08
Cash Conversion Cycle	-47.43	-3.86	32.22	105.80	105.23

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.